Methods and compositions for the prognosis and treatment of relapsed leukemia
AssigneeNew York University
InventorsWilliam L. Carroll, Julia A. Meyer
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of prognosing relapsed leukemia in a subject. These methods are based on the detection of one or more relapse-specific gene mutations in a patient sample. The present invention further relates to methods of preventing and treating relapse leukemia in a subject based on the determined prognosis of the subject.
Claims50
A method of determining a subject's risk of developing relapse leukemia, said method comprising:
- providing an isolated biological sample from a subject having leukemia;
- contacting the sample with one or more reagents suitable for detecting the presence or absence of one or more mutations in one or more genes selected from the group consisting of NT5C2, RGS12, LPHN1, CAND1, PRMT2,NIPSNAP1, USP7, TULP4, CBX3, COBRA1, SDF2, FBXO3, SCARF1, NEGR1, DPH5, SMEK2, MIER3, DOPEY1, ZNF192, EVI2A, GSPT2, and MYC;
- detecting the presence or absence of the one or more mutations in the one or more genes based on said contacting;
- and
- determining the subject's prognosis based on said detecting, wherein the presence of the one or more mutations in the one or more said genes predicts an increased likelihood the subject will develop relapse leukemia.
4-7. (canceled)
9-12. (canceled)
(canceled)
(canceled)
A method of treating a subject having leukemia comprising:
- selecting a subject having leukemia and one or more mutations in one or more genes selected from the group consisting of NT5C2, RGS12, LPHN1, CAND1, PRMT2, NIPSNAP1, USP7, TULP4, CBX3, COBRA1, SDF2, FBXO3, SCARF1, NEGR1, DPH5, SMEK2, MIER3, DOPEY1, ZNF192, EVI2A, GSPT2, and MYC and
- administering a therapy suitable for treating relapse leukemia to the selected subject.
44-47. (canceled)
(canceled)
A method of preventing or treating relapsed leukemia in a subject comprising:
- selecting a subject having one or more NT5C2 gene mutations and
- administering to the selected subject an agent that inhibits NT5C2 gene expression and/or NT5C2 encoded enzyme activity under conditions effective to prevent or treat the relapsed leukemia in the subject.
53-56. (canceled)
(canceled)
61-63. (canceled)
Dependencies are inferred from the claim text.